As previously informed, at the end of 2019, IDL Biotech signed a cooperation agreement with the Chinese company Zecen Biotech, regarding automation of the tumor marker TPS® on all Zecen Biotech’s instruments. The development project has proceeded very well and the first phase has been completed. Thus, the last phase before launch now begins. The hope is that the product will be available on the Chinese market by the end of 2021.
Read the full press release here (swedish)